Učitavanje...
Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is approved for adjunctive treatment of focal seizures, with or without secondarily generalized seizures, and for primary generalized tonic–clonic seizures in patients with epile...
Spremljeno u:
| Izdano u: | Epilepsy Behav Case Rep |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916525/ https://ncbi.nlm.nih.gov/pubmed/29707476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebcr.2017.11.001 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|